NL8500724A - Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. - Google Patents

Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. Download PDF

Info

Publication number: NL8500724A
Authority: NL; Netherlands
Prior art keywords: phase; limiting; cellulose; housing; granulate
Prior art date: 1985-03-13

Application number

NL8500724A

Other languages

English (en)

Dutch (nl)

Original Assignee

Univ Groningen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-13

Filing date

1985-03-13

Publication date

1986-10-01

1985-03-13 Application filed by Univ Groningen filed Critical Univ Groningen

1985-03-13 Priority to NL8500724A priority Critical patent/NL8500724A/nl

1986-03-10 Priority to EP86200384A priority patent/EP0196700B1/fr

1986-03-10 Priority to AT86200384T priority patent/ATE71521T1/de

1986-03-10 Priority to DE8686200384T priority patent/DE3683385D1/de

1986-03-10 Priority to US06/838,248 priority patent/US4708874A/en

1986-03-12 Priority to AU54651/86A priority patent/AU578577B2/en

1986-03-12 Priority to CA000503919A priority patent/CA1265449A/fr

1986-03-12 Priority to DK114886A priority patent/DK170244B1/da

1986-03-13 Priority to JP61058020A priority patent/JPH0776171B2/ja

1986-10-01 Publication of NL8500724A publication Critical patent/NL8500724A/nl

Links

238000000034 method Methods 0.000 title claims description 17
239000013543 active substance Substances 0.000 title claims description 14
238000004519 manufacturing process Methods 0.000 title claims description 8
239000008187 granular material Substances 0.000 claims abstract description 75
239000000203 mixture Substances 0.000 claims abstract description 57
239000002245 particle Substances 0.000 claims abstract description 43
239000000463 material Substances 0.000 claims abstract description 25
239000004480 active ingredient Substances 0.000 claims abstract description 14
239000007788 liquid Substances 0.000 claims abstract description 14
239000000126 substance Substances 0.000 claims abstract description 12
230000035515 penetration Effects 0.000 claims abstract description 8
239000002195 soluble material Substances 0.000 claims abstract description 8
239000003814 drug Substances 0.000 claims description 27
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
235000019359 magnesium stearate Nutrition 0.000 claims description 10
229920000642 polymer Polymers 0.000 claims description 8
239000002198 insoluble material Substances 0.000 claims description 7
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
239000002202 Polyethylene glycol Substances 0.000 claims description 5
229920002125 Sokalan® Polymers 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
229920000178 Acrylic resin Polymers 0.000 claims description 4
239000004925 Acrylic resin Substances 0.000 claims description 4
239000001856 Ethyl cellulose Substances 0.000 claims description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
230000004888 barrier function Effects 0.000 claims description 4
239000000470 constituent Substances 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
229920001249 ethyl cellulose Polymers 0.000 claims description 4
235000019325 ethyl cellulose Nutrition 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
239000000377 silicon dioxide Substances 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 3
235000010980 cellulose Nutrition 0.000 claims description 3
229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
-1 fatty acid esters Chemical class 0.000 claims description 3
230000002209 hydrophobic effect Effects 0.000 claims description 3
229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 3
229920002689 polyvinyl acetate Polymers 0.000 claims description 3
239000011118 polyvinyl acetate Substances 0.000 claims description 3
239000004800 polyvinyl chloride Substances 0.000 claims description 3
229920000915 polyvinyl chloride Polymers 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
235000012239 silicon dioxide Nutrition 0.000 claims description 3
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
239000001993 wax Substances 0.000 claims description 3
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
108010010803 Gelatin Proteins 0.000 claims description 2
229920000881 Modified starch Polymers 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
229920013820 alkyl cellulose Polymers 0.000 claims description 2
235000013871 bee wax Nutrition 0.000 claims description 2
239000012166 beeswax Substances 0.000 claims description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
239000008116 calcium stearate Substances 0.000 claims description 2
235000013539 calcium stearate Nutrition 0.000 claims description 2
239000004359 castor oil Substances 0.000 claims description 2
235000019438 castor oil Nutrition 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
150000002191 fatty alcohols Chemical class 0.000 claims description 2
229920000159 gelatin Polymers 0.000 claims description 2
235000019322 gelatine Nutrition 0.000 claims description 2
235000011852 gelatine desserts Nutrition 0.000 claims description 2
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 2
235000019426 modified starch Nutrition 0.000 claims description 2
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
239000004584 polyacrylic acid Substances 0.000 claims description 2
229920001515 polyalkylene glycol Polymers 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
239000001768 carboxy methyl cellulose Substances 0.000 claims 1
235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
239000004203 carnauba wax Substances 0.000 claims 1
235000013869 carnauba wax Nutrition 0.000 claims 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
238000013270 controlled release Methods 0.000 abstract description 10
239000011159 matrix material Substances 0.000 abstract description 3
239000011148 porous material Substances 0.000 abstract description 2
230000000452 restraining effect Effects 0.000 abstract 2
239000003826 tablet Substances 0.000 description 46
238000002360 preparation method Methods 0.000 description 30
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 24
229940079593 drug Drugs 0.000 description 23
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
229960000278 theophylline Drugs 0.000 description 17
229920003134 Eudragit® polymer Polymers 0.000 description 16
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 16
239000000454 talc Substances 0.000 description 13
229910052623 talc Inorganic materials 0.000 description 13
229960000541 cetyl alcohol Drugs 0.000 description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
239000008118 PEG 6000 Substances 0.000 description 11
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 11
239000008101 lactose Substances 0.000 description 11
229960001375 lactose Drugs 0.000 description 11
235000011837 pasties Nutrition 0.000 description 11
238000001035 drying Methods 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
238000002156 mixing Methods 0.000 description 10
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000000576 coating method Methods 0.000 description 6
238000000605 extraction Methods 0.000 description 6
210000001035 gastrointestinal tract Anatomy 0.000 description 6
239000011248 coating agent Substances 0.000 description 5
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
238000002844 melting Methods 0.000 description 4
230000008018 melting Effects 0.000 description 4
239000000843 powder Substances 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
238000007711 solidification Methods 0.000 description 4
230000008023 solidification Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
238000007906 compression Methods 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
238000007873 sieving Methods 0.000 description 3
INQSMEFCAIHTJG-UHFFFAOYSA-N 1,3-dimethyl-7h-purine-2,6-dione;hydrate Chemical compound O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 INQSMEFCAIHTJG-UHFFFAOYSA-N 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
239000002609 medium Substances 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
229920003152 Eudragit® RS polymer Polymers 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
FYYHWMGAXLPEAU-RNFDNDRNSA-N Magnesium-28 Chemical compound [28Mg] FYYHWMGAXLPEAU-RNFDNDRNSA-N 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
229920003082 Povidone K 90 Polymers 0.000 description 1
229920003110 Primojel Polymers 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229920001448 anionic polyelectrolyte Polymers 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229920006237 degradable polymer Polymers 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
229920000831 ionic polymer Polymers 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
238000002386 leaching Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
230000018984 mastication Effects 0.000 description 1
238000010077 mastication Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000009490 roller compaction Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8500724A 1985-03-13 1985-03-13 Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. NL8500724A (nl)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
NL8500724A NL8500724A (nl)	1985-03-13	1985-03-13	Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
EP86200384A EP0196700B1 (fr)	1985-03-13	1986-03-10	Dispositifs pour la libération contrôlée de substances actives et leur procédé de préparation
AT86200384T ATE71521T1 (de)	1985-03-13	1986-03-10	Einrichtungen fuer die kontrollierte abgabe von aktiven substanzen und verfahren zu ihrer herstellung.
DE8686200384T DE3683385D1 (de)	1985-03-13	1986-03-10	Einrichtungen fuer die kontrollierte abgabe von aktiven substanzen und verfahren zu ihrer herstellung.
US06/838,248 US4708874A (en)	1985-03-13	1986-03-10	Devices for the controlled release of active substances, as well as process for the preparation thereof
AU54651/86A AU578577B2 (en)	1985-03-13	1986-03-12	Devices for the controlled release of active substances, as well as process for the preparation thereof
CA000503919A CA1265449A (fr)	1985-03-13	1986-03-12	Dispositifs a debitage temporise de substances actives, et preparation desdits dispositifs
DK114886A DK170244B1 (da)	1985-03-13	1986-03-12	Indretning til kontrolleret afgivelse af aktive substanser samt fremgangsmåde til fremstilling af en sådan indretning
JP61058020A JPH0776171B2 (ja)	1985-03-13	1986-03-13	１つ又はそれ以上の活性成分を液に調整放出する組成物及びその調整方法

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8500724A NL8500724A (nl)	1985-03-13	1985-03-13	Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
NL8500724		1985-03-13

Publications (1)

Publication Number	Publication Date
NL8500724A true NL8500724A (nl)	1986-10-01

Family

ID=19845674

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8500724A NL8500724A (nl)	1985-03-13	1985-03-13	Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.

Country Status (9)

Country	Link
US (1)	US4708874A (fr)
EP (1)	EP0196700B1 (fr)
JP (1)	JPH0776171B2 (fr)
AT (1)	ATE71521T1 (fr)
AU (1)	AU578577B2 (fr)
CA (1)	CA1265449A (fr)
DE (1)	DE3683385D1 (fr)
DK (1)	DK170244B1 (fr)
NL (1)	NL8500724A (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4507832A (en) *	1982-09-23	1985-04-02	Technology Consulting Corporation	Method and apparatus for the continuous treatment of yarn
SE455836B (sv) *	1985-10-11	1988-08-15	Haessle Ab	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
JPS62103012A (ja) *	1985-10-23	1987-05-13	Eisai Co Ltd	多重顆粒
US4837032A (en) *	1986-02-04	1989-06-06	Farval Ag	Theophylline sustained release tablet
US4970075A (en) *	1986-07-18	1990-11-13	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
US4861598A (en) *	1986-07-18	1989-08-29	Euroceltique, S.A.	Controlled release bases for pharmaceuticals
NZ222698A (en) *	1987-01-08	1990-02-26	Squibb & Sons Inc	Bioadhesive suppository formulations comprising a medicament, water, a hydrocolloid and low melting point base
US5015480A (en) *	1987-11-25	1991-05-14	Eli Lilly And Company	Film coating formulations
JP2643222B2 (ja) *	1988-02-03	1997-08-20	エーザイ株式会社	多重層顆粒
US5196203A (en) *	1989-01-06	1993-03-23	F. H. Faulding & Co. Limited	Theophylline dosage form
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
US5002774A (en) *	1989-06-08	1991-03-26	Erbamont, Inc.	Sustained release pharmaceutical tablet
DE4127665A1 (de) *	1991-08-22	1993-02-25	Beiersdorf Ag	Galenische matrix
DE4138513A1 (de) *	1991-11-23	1993-05-27	Basf Ag	Feste pharmazeutische retardform
US5266331A (en) *	1991-11-27	1993-11-30	Euroceltique, S.A.	Controlled release oxycodone compositions
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5968551A (en) *	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
NZ260408A (en) *	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
US7740881B1 (en)	1993-07-01	2010-06-22	Purdue Pharma Lp	Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) *	1993-07-27	1999-03-09	Euro-Celtique S.A.	Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR950007873A (ko) *	1993-09-20	1995-04-15	후꾸하라 요시하루	생리 활성 물질 지속 방출형의 의약 제제
FR2718020B1 (fr) *	1994-04-01	1996-05-31	Biotec Centre Sa	Composition galénique mucoadhésive hétérofonctionnelle.
AT403988B (de) *	1994-05-18	1998-07-27	Lannacher Heilmittel	Festes orales retardpräparat
WO1995034200A1 (fr) *	1994-06-10	1995-12-21	Fernz Corporation Limited	Composition biodegradable a liberation constante
US5744164A (en) *	1994-12-16	1998-04-28	Nestec S.A.	Sustained release microparticulate caffeine formulation
DE29502547U1 (de) *	1995-02-16	1995-03-30	Röhm GmbH, 64293 Darmstadt	Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
US5695781A (en) *	1995-03-01	1997-12-09	Hallmark Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers
US6083532A (en) *	1995-03-01	2000-07-04	Duramed Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5773031A (en) *	1996-02-27	1998-06-30	L. Perrigo Company	Acetaminophen sustained-release formulation
US6251430B1 (en) *	1998-02-04	2001-06-26	Guohua Zhang	Water insoluble polymer based sustained release formulation
US6806294B2 (en)	1998-10-15	2004-10-19	Euro-Celtique S.A.	Opioid analgesic
EP1126826B3 (fr)	1998-11-02	2019-05-15	Alkermes Pharma Ireland Limited	Composition de methylphenidate a liberation modifiee multiparticulaire
US20090297597A1 (en) *	1998-11-02	2009-12-03	Gary Liversidge	Modified Release Ticlopidine Compositions
US20060240105A1 (en) *	1998-11-02	2006-10-26	Elan Corporation, Plc	Multiparticulate modified release composition
US20090149479A1 (en) *	1998-11-02	2009-06-11	Elan Pharma International Limited	Dosing regimen
US20070122481A1 (en) *	1998-11-02	2007-05-31	Elan Corporation Plc	Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US6340478B1 (en) *	1999-06-07	2002-01-22	Bio Dar Ltd.	Microencapsulated and controlled-release herbal formulations
US6555139B2 (en)	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
IL131508A (en)	1999-08-19	2006-12-10	David Cohen	Microencapsulated and controlled-release formulations of isoflavone from enriched fractions of soy and other plants
AU764453B2 (en) *	1999-10-29	2003-08-21	Euro-Celtique S.A.	Controlled release hydrocodone formulations
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
AT414205B (de) *	2000-06-20	2006-10-15	Vis Vitalis Lizenz & Handels	Verfahren zur herstellung von ungesättigtem fettsäure-trockenkonzentrat
DE10031043A1 (de) *	2000-06-26	2002-02-14	Bayer Ag	Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
MXPA03003895A (es)	2000-10-30	2003-07-28	Euro Celtique Sa	Formulaciones de hidrocodona de liberacion controlada.
UA81224C2 (uk)	2001-05-02	2007-12-25	Euro Celtic S A	Дозована форма оксикодону та її застосування
US20110104214A1 (en) *	2004-04-15	2011-05-05	Purdue Pharma L.P.	Once-a-day oxycodone formulations
KR20030060730A (ko) *	2002-01-09	2003-07-16	하나제약 주식회사	난용성 약물의 서방화 제제 조성물
HRP20020124A2 (en) *	2002-02-11	2003-10-31	Pliva D D	Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
US20080220074A1 (en) *	2002-10-04	2008-09-11	Elan Corporation Plc	Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
KR100540037B1 (ko) *	2003-06-27	2005-12-29	하나제약 주식회사	펠로디핀의 지속성 정제 및 그 제조방법
KR100914426B1 (ko) *	2004-08-06	2009-08-27	닛뽕소다 가부시키가이샤	용출 제어된 농약 제제
US20060121112A1 (en) *	2004-12-08	2006-06-08	Elan Corporation, Plc	Topiramate pharmaceutical composition
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
JP2008525313A (ja)	2004-12-27	2008-07-17	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬の安定化方法
US20060160852A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20060159753A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Matrix type sustained-release preparation containing basic drug or salt thereof
KR20070102563A (ko) *	2005-01-26	2007-10-18	엘란 파마 인터내셔널 리미티드	정신병치료제를 함유하는 조절방출형 조성물
US20070298098A1 (en) *	2005-02-16	2007-12-27	Elan Pharma International Limited	Controlled Release Compositions Comprising Levetiracetam
AU2006235483B2 (en) *	2005-04-12	2010-11-25	Elan Pharma International Limited	Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
WO2007037790A2 (fr) *	2005-06-08	2007-04-05	Elan Corporation, Plc	Compositions famciclovir à libération modifiée
US20070224233A1 (en) *	2005-08-05	2007-09-27	Nippon Soda Co., Ltd	Controlled-Release Agricultural Chemical Formulation
BRPI0707471A2 (pt) *	2006-02-06	2011-05-03	Nippon Soda Co	composição de resina contendo substáncia quìmica agrìcola de liberação controlada, método de produção da mesma e formulação quìmica agrìcola
US20070286903A1 (en) *	2006-06-13	2007-12-13	Becicka Brian T	Composition and method for taste masking
US20080069871A1 (en) *	2006-07-21	2008-03-20	Vaughn Jason M	Hydrophobic abuse deterrent delivery system
US8992898B2 (en)	2010-04-17	2015-03-31	Shannon Elizabeth Klingman	Antiperspirants and deodorants
US20140179615A1 (en) *	2012-07-12	2014-06-26	Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.	Glutathione and Acetaminophen Composition and Preparation Method Thereof
ES2821528T3 (es)	2012-11-14	2021-04-26	Grace W R & Co	Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CA2902911C (fr)	2014-10-31	2017-06-27	Purdue Pharma	Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10645931B2 (en)	2016-12-15	2020-05-12	Wellmark International	Extended release formulation
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2793979A (en) *	1953-03-30	1957-05-28	Smith Kline French Lab	Method of making a sustained release pharmaceutical tablet and product of the method
US2996431A (en) *	1953-12-16	1961-08-15	Barry Richard Henry	Friable tablet and process for manufacturing same
US3166476A (en) *	1961-09-01	1965-01-19	Lowey Hans	Powder based tablets
BE640616A (fr) *	1962-12-19
IE32806B1 (en) *	1968-05-21	1973-12-12	American Home Prod	Sustained release drug composition
US3634584A (en) *	1969-02-13	1972-01-11	American Home Prod	Sustained action dosage form
GB1405088A (en) *	1971-06-03	1975-09-03	Mundipharma Ag	Slow release formulation
US3965256A (en) *	1972-05-16	1976-06-22	Synergistics	Slow release pharmaceutical compositions
DE2426811A1 (de) *	1974-06-04	1976-01-08	Klinge Co Chem Pharm Fab	Verfahren zur herstellung von retard-tabletten
US4139589A (en) *	1975-02-26	1979-02-13	Monique Beringer	Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
GB1576376A (en) *	1977-03-30	1980-10-08	Benzon As Alfred	Multiple-unit drug dose
FR2403080A1 (fr) *	1977-09-15	1979-04-13	Heyden Chem Fab	Preparation de nitrofurantoine a effet retard pour administration orale et son procede de fabrication
US4210139A (en) *	1979-01-17	1980-07-01	Alza Corporation	Osmotic device with compartment for governing concentration of agent dispensed from device
JPS55153715A (en) *	1979-05-18	1980-11-29	Nikken Kagaku Kk	Prolonged granule of theophylline
JPS5661311A (en) *	1979-10-25	1981-05-26	Fujisawa Pharmaceut Co Ltd	Thial amide or prolonged pharmaceutical preparation comprising its salt
JPS56122311A (en) *	1980-02-29	1981-09-25	Eisai Co Ltd	Lasting theophylline pharmaceutical composition
JPS5826816A (ja) *	1981-08-11	1983-02-17	Teisan Seiyaku Kk	球形顆粒からなる持続性複合顆粒剤
JPS5839618A (ja) *	1981-09-04	1983-03-08	Chugai Pharmaceut Co Ltd	持続性積層錠剤
JPS5883613A (ja) *	1981-11-10	1983-05-19	Toa Eiyou Kagaku Kogyo Kk	硝酸イソソルビト−ル製剤
DE3218150C2 (de) *	1982-05-14	1986-09-25	Akzo Gmbh, 5600 Wuppertal	Wirkstoff enthaltender Körper für die Langzeitabgabe sowie Verfahren zu dessen Herstellung
US4415547A (en) *	1982-06-14	1983-11-15	Sterling Drug Inc.	Sustained-release pharmaceutical tablet and process for preparation thereof
DK152744C (da) *	1982-08-13	1988-10-31	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
DK151608C (da) *	1982-08-13	1988-06-20	Benzon As Alfred	Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4610870A (en) *	1984-10-05	1986-09-09	E. R. Squibb & Sons, Inc.	Controlled release formulation
US4772475A (en) *	1985-03-08	1988-09-20	Yamanouchi Pharmaceutical Co., Ltd.	Controlled-release multiple units pharmaceutical formulation

1985
- 1985-03-13 NL NL8500724A patent/NL8500724A/nl not_active Application Discontinuation
1986
- 1986-03-10 AT AT86200384T patent/ATE71521T1/de not_active IP Right Cessation
- 1986-03-10 US US06/838,248 patent/US4708874A/en not_active Expired - Fee Related
- 1986-03-10 DE DE8686200384T patent/DE3683385D1/de not_active Expired - Lifetime
- 1986-03-10 EP EP86200384A patent/EP0196700B1/fr not_active Expired - Lifetime
- 1986-03-12 AU AU54651/86A patent/AU578577B2/en not_active Ceased
- 1986-03-12 DK DK114886A patent/DK170244B1/da not_active IP Right Cessation
- 1986-03-12 CA CA000503919A patent/CA1265449A/fr not_active Expired
- 1986-03-13 JP JP61058020A patent/JPH0776171B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0196700A1 (fr)	1986-10-08
JPS61251617A (ja)	1986-11-08
AU5465186A (en)	1986-09-18
DK114886A (da)	1986-09-14
DK114886D0 (da)	1986-03-12
ATE71521T1 (de)	1992-02-15
US4708874A (en)	1987-11-24
CA1265449C (fr)	1990-02-06
DK170244B1 (da)	1995-07-17
JPH0776171B2 (ja)	1995-08-16
CA1265449A (fr)	1990-02-06
AU578577B2 (en)	1988-10-27
DE3683385D1 (de)	1992-02-27
EP0196700B1 (fr)	1992-01-15

Legal Events

Date	Code	Title	Description
1986-10-01	A1B	A search report has been drawn up
1987-11-02	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8500724A (nl)	1986-10-01	Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
EP0235986B2 (fr)	1999-04-21	Formulation à libération lente
EP0523847B1 (fr)	1996-04-24	Enrobage masquant le mauvais goût pour la préparation de comprimés à mâcher pharmaceutiques
US5631023A (en)	1997-05-20	Method for making freeze dried drug dosage forms
US4748023A (en)	1988-05-31	Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
CA1324081C (fr)	1993-11-09	Agent pharmaceutique a liberation lente
RU2101009C1 (ru)	1998-01-10	Твердая лекарственная форма для орального применения с замедленным высвобождением активного вещества и способ ее изготовления (варианты)
EP0194838A2 (fr)	1986-09-17	Formulation pharmaceutique à libération contrôlée
NZ201008A (en)	1985-11-08	Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
JPH0122245B2 (fr)	1989-04-25
NL8500856A (nl)	1985-10-16	Bij opslag stabiele, snel uiteenvallende geperste voortbrengsels van een farmaceutisch werkzame stof alsmede een werkwijze ter vervaardiging ervan.
CZ20023379A3 (cs)	2003-01-15	Farmaceutické kompozice obsahující fluvastatin a hydroxypropylmethylcelulózu a způsoby prevence tvorby gelů hydratované hydroxypropylmethylcelulózy v těchto kompozicích
FI96095C (fi)	1996-05-10	Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi
NL8601961A (nl)	1987-02-16	Granulaire vorm van farmaceutisch werkzame stoffen met vertraagde afgifte.
JPH02104A (ja)	1990-01-05	薬物放出速度調節型製剤
KR970007899B1 (ko)	1997-05-17	맛 은폐를 위한 수단을 포함하는 저작가능한 의약 정제
US7364755B2 (en)	2008-04-29	Modified calcium phosphate excipient
CA2212309C (fr)	2000-08-08	Formes posologiques orales solides a liberation prolongee de medicaments faiblement solubles dans l'eau
US3632778A (en)	1972-01-04	Tablets containing l-dopa
JPS63165318A (ja)	1988-07-08	光の影響に対して安定化したニフェディピン濃縮物及びその製造方法
US3453360A (en)	1969-07-01	Universally useful stock material for manufacturing plastic dosage units by compression tableting processes
CA2658512A1 (fr)	2008-01-31	Formes posologiques lyophilisees a dissolution/desintegration orale contenant des particules protegees
EP0425298B1 (fr)	1994-04-13	Préparation à libération retardée d'un chlorhydrate d'un médicament basique
US4601895A (en)	1986-07-22	Delayed-action acetylsalicylic acid formulations for oral administration
JPH03500288A (ja)	1991-01-24	徐放性ニフェジピン製剤